Cylembio

News

IO Biotech's cancer vaccine Cylembio failed to hit the mark in a phase 3 melanoma trial – but the company hopes to file for approval regardless.

News

A research consortium that aims to make the UK a leader in AI-driven drug discovery, OpenBind, has hit its first major milestone.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.